2 most recent filings and news items mentioning ANTX. Updated every 60 seconds.
RegulatoryJun 4, 2026Positive
AN2 Therapeutics announced positive results for AN2-502998, achieving 100% parasite elimination in nonhuman primates with a favorable safety profile in Phase 1 testing. The company plans to advance the oral CPSF3 inhibitor to Phase 2 studies for chronic Chagas disease, addressing
View filing at SEC.gov →
OfferingMay 22, 2026Neutral
Anteris Technologies Global Corp. entered into a Common Stock Sales Agreement with TD Securities to issue up to $250 million in shares through an at-the-market offering. The agreement provides the company with flexible capital raising capacity under its existing S-3 registration
View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.